UEEC.OQBUnited Health Products, INC

10-Q: United Health Products Reports Q1 2025 Results, Focus Remains on FDA Approval

Sentiment:

Quarterly Report

📋All filings for United Health Products, INC
🔒Login to Follow

United Health Products reports no revenue for Q1 2025 as it continues to pursue FDA Premarket Approval for its CelluSTAT hemostatic gauze.

Delay expectedThe FDA's 180-day PMA application review period is currently paused while UHP addresses the FDA's requests for additional data.
Capital raiseThe company's ability to continue as a going concern is dependent on securing additional financing.The company entered into a common stock purchase agreement (CSPA) with White Lion, which gives the Company the right, but not the obligation, to require White Lion to purchase up to $10,000,000 of the Companys common stock.The sale of additional equity or convertible debt securities would be dilutive to our shareholders.
Worse than expectedThe company's net loss increased significantly compared to the same period last year.The company's cash position has deteriorated substantially.Operating expenses have increased significantly.

Summary

  • United Health Products (UHP) reported its Q1 2025 financial results, showing no revenue for the quarter.
  • The company is focused on obtaining FDA Premarket Approval (PMA) for its CelluSTAT hemostatic gauze.
  • Operating expenses increased significantly to $1,489,216, primarily due to a rise in stock-based compensation.
  • The net loss for the quarter was $1,531,659, compared to a net loss of $451,938 in Q1 2024.
  • As of March 31, 2025, UHP had a negative working capital of $1,771,186 and cash and cash equivalents of $4,914.
  • The company is exploring potential commercial partnerships and a possible sale or merger in anticipation of FDA approval.
  • UHP's ability to continue as a going concern is dependent on securing additional financing and achieving its business goals.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with increasing losses, decreasing cash, and a paused FDA approval process. While the company is exploring strategic options, the overall sentiment is negative due to the significant financial challenges and regulatory uncertainty.

Positives

  • The company is actively working to address the FDA's concerns regarding its PMA application.
  • UHP is exploring strategic options, including potential partnerships, a sale, or a merger, to maximize shareholder value.
  • The CelluSTAT technology is protected by patents through 2029.
  • The company has received approximately $3.2 million in proceeds from White Lion to pay for its operations and finalization of its Class III PMA application.

Negatives

  • The company reported no revenue for the quarter.
  • Operating expenses have increased significantly, leading to a larger net loss.
  • The company has a negative working capital of $1,771,186.
  • There is substantial doubt about the company's ability to continue as a going concern.
  • The FDA's PMA application review is currently paused.
  • The company's disclosure controls and procedures were not effective as of March 31, 2025.

Risks

  • The company's ability to obtain FDA approval for CelluSTAT is uncertain.
  • The company's financial condition raises concerns about its ability to continue as a going concern.
  • The company relies on external financing, which may not be available on favorable terms.
  • The company's success depends on its ability to successfully commercialize CelluSTAT.
  • The company's disclosure controls and procedures were not effective as of March 31, 2025.

Future Outlook

The company is focused on obtaining FDA approval for CelluSTAT and is exploring strategic options, including potential partnerships, a sale, or a merger, to maximize shareholder value. The company's ability to continue as a going concern is dependent on securing additional financing and achieving its business goals.

Management Comments

  • Management believes there is an opportunity for CelluSTAT products to address unmet needs in several medical applications.
  • Management is unable to predict if or when a Covered Transaction or Triggering Event under the RSU Agreements governing the restricted stock units will occur.

Industry Context

The hemostatic gauze market is competitive, with a mix of established players and emerging companies. UHP is targeting the Class III human surgical markets, which offer premium pricing but require stringent regulatory approval. The company's strategy of seeking partnerships or a sale/merger reflects the challenges of independently commercializing medical devices in this sector.

Comparison to Industry Standards

  • Ethicon's Surgicel Original is mentioned as the standard of care in the hemostatic gauze market.
  • The company's 2019 clinical trial showed statistically superior performance in time to hemostasis using CelluSTAT over Ethicon's Surgicel Original.
  • The company is seeking to compete with established Class III market participants in the hemostatic agent market.

Related Party Transactions

  • Convertible notes payable related parties totaled $500,000 as of March 31, 2025 and December 31, 2024.
  • During the three months ended March 31, 2025, the Company's Chief Executive Officer advanced the Company $20,000 to pay for operating expenses.

Stakeholder Impact

  • Shareholders face potential dilution from future equity offerings.
  • Employees face uncertainty due to the company's financial condition and strategic review.
  • Customers may experience delays in product availability due to the paused FDA approval process.
  • Creditors face increased risk due to the company's negative working capital and going concern uncertainty.

Next Steps

  • Address the FDA's requests for additional data to resume the PMA application review process.
  • Continue to evaluate potential commercial partnerships in anticipation of an FDA decision on the Class III PMA application.
  • Secure additional financing to support operations and development activities.

Key Dates

DateDescription
2012CelluSTAT received FDA 510(k) approval for superficial bleeding.
March 2024UHP submitted a full application for Premarket Approval to the FDA.
June 20, 2024The Company and White Lion amended the CSPA (the Second Amendment).
June 2024FDA responded with a Deficiencies Letter listing approximately 40 specific comments and requests for additional information.
June 26, 2024The Company filed a registration statement on Form S-1 to register for resale an additional 15,000,000 common shares related to CSPA.
July 29, 2024The Company's S-1 registration statement was declared effective by the SEC.
August 5, 2024The Company entered into a $150,000 promissory note with a third-party lender.
August 2024UHP submitted a Submission Issue Request (SIR) to the FDA outlining its plan to address and respond to the FDA's comments.
September 23 through October 4, 2024The FDA conducted a Bioresearch Monitoring Program (BIMO) Inspection of our records and procedures relating to our clinical study, following which the FDA delivered its Inspectional Observations on Form 483.
October 25, 2024UHP submitted its response to the FDA's observations.
December 15, 2023The Company entered into amendments on the above convertible notes, which extended the maturity date to December 31, 2024 and increased the interest rate from 10% to 13%, effective January 1, 2024.
December 16, 2024The Company rolled the $150,000 promissory note into a convertible note agreement with this third-party lender.
December 20, 2024The Company entered into amendments on the above convertible notes, which extended the maturity date to December 31, 2026.
March 31, 2025End of the quarterly period.
May 2, 2025The number of shares issued and outstanding of the Registrants Common Stock was 257,133,222.
May 5, 2025Date of report filing.
May 31, 2026End date of the 36-month operating lease.

Keywords

CelluSTAT, hemostatic gauze, FDA, Premarket Approval, financial results, operating expenses, net loss, going concern, UHP, United Health Products

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.